Krilogy Financial LLC Has $631,000 Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Krilogy Financial LLC trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 58.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,587 shares of the biopharmaceutical company’s stock after selling 2,235 shares during the period. Krilogy Financial LLC’s holdings in Alnylam Pharmaceuticals were worth $631,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $29,000. Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $36,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ALNY. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Royal Bank Of Canada reduced their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Wells Fargo & Company reduced their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Weiss Ratings cut shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $472.78.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at $7,704,867.84. The trade was a 8.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 6,958 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $2,157,536.64. Following the completion of the sale, the chief executive officer directly owned 85,662 shares in the company, valued at $26,562,072.96. This trade represents a 7.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 38,656 shares of company stock worth $12,370,696. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $310.58 on Thursday. The stock has a market cap of $41.44 billion, a P/E ratio of 181.63 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $238.62 and a one year high of $495.55. The company has a fifty day moving average price of $322.14 and a 200 day moving average price of $383.15. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.65) earnings per share. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.